Detection and pharmacokinetics of salmeterol in thoroughbred horses following inhaled administration.

The research article focuses on determining the detection time of the drug salmeterol in racehorses following inhaled administration, to comply with racing regulations while ensuring effective treatment for horses with inflammatory airway disease.

Introduction to the Study

• The research starts from the premise that salmeterol, a synthetic beta-2-adrenergic receptor agonist, is used for treating bronchospasm connected to inflammatory airway disease in horses. However, under the regulations of the British Horseracing Authority, horses cannot compete with clinically effective doses of medications. Therefore, there’s a need to establish a detection time frame for the drug following its administration to ensure compliance with these rules.

Administration of Salmeterol and Sample Collection

• In the study, salmeterol xinafoate was administered via inhalation to six horses twice per day, for 4.5 days.
• After administering the drug, urine and blood samples were collected from the horses for up to 103 hours following the treatment.
• The collected samples were subsequently processed using solid phase extraction – a method used to isolate and concentrate the drug from the samples.

Analytical Method Development and Results

• The researchers then used Ultra high performance tandem mass spectrometry (UPLC-MS/MS), a highly sensitive and accurate analytical technique, to detect and measure salmeterol in the horse samples.
• The lower limit of quantification (LLOQ) of the method was established at 10 pg/mL, representing the minimum concentration of the drug in horse blood or urine that could be reliably quantified using the technique.
• The study found that most of the drug’s concentration in horse plasma (i.e., its blood minus the blood cells) fell below the LLOQ following its last administration implying that it could not be adequately used for pharmacokinetic analysis, which is the study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
• However, the analysis of the urine samples indicated a half-life of the drug consistent with its duration of a pharmacological effect – the period during which the drug is active within the body.
• Using pharmacokinetic modelling, an average estimated urine concentration of salmeterol at steady-state was obtained. This was used to estimate a marker of effective lung concentration.

Conclusion

• Based on these findings, potential detection times for the drug were calculated so as to set “safety factors”. These safety factors ensure that racehorses are compliant with racing regulations, while also ensuring effective treatment for conditions like inflammatory airway disease.